Parathyroid Hormone Receptor Directly Interacts with Dishevelled to Regulate Beta-Catenin Signaling and Osteoclastogenesis
Overview
Affiliations
Bone growth and remodeling depend upon the opposing rates of bone formation and resorption. These functions are regulated by intrinsic seven transmembrane-spanning receptors, the parathyroid hormone receptor (PTH1R) and frizzled (FZD), through their respective ligands, parathyroid hormone (PTH) and Wnt. FZD activation of canonical beta-catenin signaling requires the adapter protein Dishevelled (Dvl). We identified a Dvl-binding motif in the PTH1R. Here, we report that the PTH1R activates the beta-catenin pathway by directly recruiting Dvl, independent of Wnt or LRP5/6. PTH1R coimmunoprecipitated with Dvl. Deleting the carboxyl-terminal PTH1R PDZ-recognition domain did not abrogate PTH1R-Dvl interactions; nor did truncating the receptor at position 480. However, further deletion eliminating the putative Dvl recognition domain abolished PTH1R interactions with Dvl. PTH activated beta-catenin in a time- and concentration-dependent manner and translocated beta-catenin to the nucleus. beta-Catenin activation was inhibited by Dvl2 dominant negatives and by short hairpin RNA sequences targeted against Dvl2. PTH-induced osteoclastogenesis was also inhibited by Dvl2 dominant negative mutants. These findings demonstrate that G protein-coupled receptors other than FZD directly activate beta-catenin signaling, thereby mimicking many of the functions of the canonical Wnt-FZD pathway. The distinct modes whereby FZD and PTH1R activate beta-catenin control convergent or divergent effects on osteoblast differentiation, and osteoclastogenesis may arise from PTH1R-induced second messenger phosphorylation.
Abdullah Sani N, Kamaruddin N, Soelaiman I, Pang K, Chin K, Ramli E Biomedicines. 2025; 13(1).
PMID: 39857826 PMC: 11762645. DOI: 10.3390/biomedicines13010243.
Avgoustou P, Jailani A, Desai A, Roberts D, Lilley E, Stothard G Front Pharmacol. 2024; 15:1455231.
PMID: 39376604 PMC: 11456535. DOI: 10.3389/fphar.2024.1455231.
New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies.
Nag J, Appasamy P, Malka H, Sedley S, Bar-Shavit R Int J Mol Sci. 2024; 25(15).
PMID: 39125653 PMC: 11311281. DOI: 10.3390/ijms25158083.
Jimenez-Ortega R, Ortega-Melendez A, Patino N, Rivera-Paredez B, Hidalgo-Bravo A, Velazquez-Cruz R Biology (Basel). 2024; 13(7).
PMID: 39056698 PMC: 11273958. DOI: 10.3390/biology13070505.
Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease.
Hu L, Chen W, Qian A, Li Y Bone Res. 2024; 12(1):39.
PMID: 38987555 PMC: 11237130. DOI: 10.1038/s41413-024-00342-8.